nach oben

Herzschrittmachertherapie + Elektrophysiologie

Erschienen in:

01.12.2013 | Schwerpunkt

Ventrikuläre Tachykardien unter Belastung

Typisches Merkmal oder prognostische Relevanz?

verfasst von: Dr. med. Jürgen Biermann, Thomas S. Faber

Erschienen in: Herzschrittmachertherapie + Elektrophysiologie | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Belastungsinduzierte ventrikuläre Tachykardien (BVT) treten beim Long-QT-Syndrom (LQTS) oder bei der katecholaminergen polymorphen ventrikulären Tachykardie (CPVT) als typisches und häufiges Merkmal auf. Bei der arrhythmogenen rechtsventrikulären Kardiomyopathie (ARVC) und der hypertrophen Kardiomyopathie (HCM) sind sie hingegen eher selten. Hier kommt den BVT in erster Linie eine prognostische Bedeutung zu. In der vorliegenden Übersicht werden die vier genannten Kardiomyopathien kurz vorgestellt und die Bedeutung von BVT für die jeweilige Kardiomyopathie genauer besprochen.

Aizawa Y, Komura S, Okada S, Chinushi M, Aizawa Y, Morita H, Ohe T (2006) Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). Int Heart J 47:381–389

Bai R, Di BL, Shivkumar K, Mohanty P, Tung R, Santangeli P, Saenz LC, Vacca M, Verma A, Khaykin Y, Mohanty S, Burkhardt JD, Hongo R, Beheiry S, Dello RA, Casella M, Pelargonio G, Santarelli P, Sanchez J, Tondo C, Natale A (2011) Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ Arrhythm Electrophysiol 4:478–485PubMedCrossRef

Collura CA, Johnson JN, Moir C, Ackerman MJ (2009) Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm 6:752–759PubMedCrossRef

Corrado D, Leoni L, Link MS, Della BP, Gaita F, Curnis A, Salerno JU, Igidbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vergara G, Delise P, Turrini P, Basso C, Naccarella F, Maddalena F, Estes NA III, Buja G, Thiene G (2003) Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 108:3084–3091PubMedCrossRef

Dorostkar PC, Eldar M, Belhassen B, Scheinman MM (1999) Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation 100:2431–2436PubMedCrossRef

Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36:2212–2218PubMedCrossRef

Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome Esteban MT, McKenna WJ (2006) Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 92:785–791PubMedCrossRef

Fisher JD, Krikler D, Hallidie-Smith KA (1999) Familial polymorphic ventricular arrhythmias: a quarter century of successful medical treatment based on serial exercise-pharmacologic testing. J Am Coll Cardiol 34:2015–2022PubMedCrossRef

Gimeno JR, Tome-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B, Lambiase P, McKenna WJ, Elliott PM (2009) Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 30:2599–2605PubMedCrossRef

10.

Hayashi M, Denjoy I, Hayashi M, Extramiana F, Maltret A, Roux-Buisson N, Lupoglazoff JM, Klug D, Maury P, Messali A, Guicheney P, Leenhardt A (2012) The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. Europace 14:1344–1351PubMedCrossRef

11.

Hobbs JB, Peterson DR, Moss AJ, McNitt S, Zareba W, Goldenberg I, Qi M, Robinson JL, Sauer AJ, Ackerman MJ, Benhorin J, Kaufman ES, Locati EH, Napolitano C, Priori SG, Towbin JA, Vincent GM, Zhang L (2006) Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 296:1249–1254PubMedCrossRef

12.

Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M (2001) A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69:1378–1384PubMedCrossRef

13.

Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, Marino M, Tiso N, Viitasalo M, Toivonen L, Stephan DA, Kontula K (2001) Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 103:485–490PubMedCrossRef

14.

Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P (1995) Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 91:1512–1519PubMedCrossRef

15.

Link MS, Wang PJ, Haugh CJ, Homoud MK, Foote CB, Costeas XB, Estes NA III (1997) Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators. J Interv Card Electrophysiol 1:41–48PubMedCrossRef

16.

Liu N, Colombi B, Raytcheva-Buono EV, Bloise R, Priori SG (2007) Catecholaminergic polymorphic ventricular tachycardia. Herz 32:212–217PubMedCrossRef

17.

Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W (2010) Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 121:1533–1541PubMedCrossRef

18.

Maron BJ (2003) Sudden death in young athletes. N Engl J Med 349:1064–1075PubMedCrossRef

19.

Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED (2003) American College of Cardiology/European society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on clinical expert Consensus documents and the European society of cardiology committee for practice guidelines. Eur Heart J 24:1965–1991PubMedCrossRef

20.

Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295–303PubMedCrossRef

21.

Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le MH, Bennett V (2003) Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421:634–639PubMedCrossRef

22.

Moss AJ, Liu JE, Gottlieb S, Locati EH, Schwartz PJ, Robinson JL (1991) Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation 84:1524–1529PubMedCrossRef

23.

Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML (2000) Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101:616–623PubMedCrossRef

24.

Pelliccia A, Zipes DP, Maron BJ (2008) Bethesda Conference #36 and the European society of cardiology consensus recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol 52:1990–1996PubMedCrossRef

25.

Perrin MJ, Angaran P, Laksman Z, Zhang H, Porepa LF, Rutberg J, James C, Krahn AD, Judge DP, Calkins H, Gollob MH (2013) Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol

26.

Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, Dubosq-Bidot L, Sebillon P, Mannens MM, Guicheney P, Wilde AA (2005) Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 42:863–870PubMedCrossRef

27.

Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A (2002) Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 106:69–74PubMedCrossRef

28.

Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA (2001) Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103:196–200PubMedCrossRef

29.

Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, Fauconnier J, Brocard J, Denjoy I, Durand P, Guicheney P, Kyndt F, Leenhardt A, Le MH, Lucet V, Mabo P, Probst V, Monnier N, Ray PF, Santoni E, Tremeaux P, Lacampagne A, Faure J, Lunardi J, Marty I (2012) Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet 21:2759–2767PubMedCrossRef

30.

Sauer AJ, Moss AJ, McNitt S, Peterson DR, Zareba W, Robinson JL, Qi M, Goldenberg I, Hobbs JB, Ackerman MJ, Benhorin J, Hall WJ, Kaufman ES, Locati EH, Napolitano C, Priori SG, Schwartz PJ, Towbin JA, Vincent GM, Zhang L (2007) Long QT syndrome in adults. J Am Coll Cardiol 49:329–337PubMedCrossRef

31.

Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D (2004) Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 109:1826–1833PubMedCrossRef

32.

Swan H, Laitinen P, Kontula K, Toivonen L (2005) Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 16:162–166PubMedCrossRef

33.

Swan H, Piippo K, Viitasalo M, Heikkila P, Paavonen T, Kainulainen K, Kere J, Keto P, Kontula K, Toivonen L (1999) Arrhythmic disorder mapped to chromosome 1q42–q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 34:2035–2042PubMedCrossRef

34.

Thiene G, Nava A, Corrado D, Rossi L, Pennelli N (1988) Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 318:129–133PubMedCrossRef

35.

Viskin S, Fish R, Zeltser D, Belhassen B, Heller K, Brosh D, Laniado S, Barron HV (2000) Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent? Heart 83:661–666PubMedCrossRef

36.

Watanabe H, van der Werf C, Roses-Noguer F, Adler A, Sumitomo N, Veltmann C, Rosso R, Bhuiyan ZA, Bikker H, Kannankeril PJ, Horie M, Minamino T, Viskin S, Knollmann BC, Till J, Wilde AA (2013) Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 10:542–547PubMedCrossRef

37.

Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G (1992) Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 86:29–37PubMedCrossRef

38.

Wichter T, Paul M, Wollmann C, Acil T, Gerdes P, Ashraf O, Tjan TD, Soeparwata R, Block M, Borggrefe M, Scheld HH, Breithardt G, Bocker D (2004) Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation 109:1503–1508PubMedCrossRef

39.

Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M (2003) Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 14:337–341PubMedCrossRef

Titel: Ventrikuläre Tachykardien unter Belastung
Typisches Merkmal oder prognostische Relevanz?
verfasst von: Dr. med. Jürgen Biermann
Thomas S. Faber
Publikationsdatum: 01.12.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Herzschrittmachertherapie + Elektrophysiologie / Ausgabe 4/2013
Print ISSN: 0938-7412
Elektronische ISSN: 1435-1544
DOI: https://doi.org/10.1007/s00399-013-0293-3

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Ventrikuläre Tachykardien unter Belastung

Typisches Merkmal oder prognostische Relevanz?

Zusammenfassung

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Hugo-von-Ziemssen-Posterpreis 2013

Jahresbericht 2011des Deutschen Herzschrittmacher- und Defibrillatorregisters

Brugada-Syndrom

Jahresbericht 2011des Deutschen Herzschrittmacher- und Defibrillatorregisters

Remote monitoring of a high-risk patient with Brugada syndrome: association of different arrhythmic manifestations

Risk stratification in arrhythmogenic right ventricular cardiomyopathy

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adipositas-Medikament auch gegen Schlafapnoe wirksam

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

Update Kardiologie